The management of metastatic melanoma has been revolutionized in recent years with the development of both targeted therapy and immunotherapy. Although potentially extending the life expectancy for patients, these therapies also significantly increase the healthcare expenditure. In this paper, we review the monthly costs for drugs approved by the FDA since 2011. Additionally, factors that affect the cost, such as dosing strategies, biomarkers, combination therapies, and political/legislative issues, will be discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
metastatic melanoma
8
strategies individualizing
4
individualizing management
4
management patients
4
patients metastatic
4
melanoma managed
4
managed care
4
care perspective
4
perspective management
4
management metastatic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!